A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

Despite rehiring hundreds of FDA, CDC and NIH employees, the Department of Health and Human Services is still a skeleton of ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.